Literature DB >> 19577628

Mechanisms in the serotype-independent pneumococcal immunity induced in mice by intranasal vaccination with the cell wall polysaccharide.

Ying-Jie Lu1, Ian Chr Skovsted, Claudette M Thompson, Porter W Anderson, Richard Malley.   

Abstract

We previously reported that cell wall polysaccharide (CWPS) given to mice intranasally with adjuvant induces serotype-independent immunity to pneumococci. Some strains make CWPS with one phosphocholine group (CWPS/1), but most express two per tetrasaccharide repeat unit (CWPS/2). Here, CWPS/1 and CWPS/2 were equally protective against colonization by CWPS/2-type pneumococci, but the related Streptococcus mitis polymer lacking phosphocholine was non-protective. Previously the protection was shown to be CD4+T cell-dependent, abrogated by antiserum to interleukin (IL)-17A, and demonstrable in antibody-defective mice. Here, CWPS failed to protect IL-17A receptor knockout mice, further indicating IL-17A-dependence. When commercial CWPS/1 was size-fractionated preparatively, the larger exceeded the smaller molecules in their capacity to prime for IL-17A responses, and only the larger protected against pneumococcal colonization. However, a CWPS-tetanus toxoid conjugate - despite raising high titers of phosphocholine antibody - was non-protective, confirming the irrelevance of humoral immunity in this model. The results strengthen the concept that IL-17A-mediated T cell immunity is inducible by zwitterionic polysaccharides with sufficient chain length to provide coiled secondary structure. Coupling CWPS to protein, which paradoxically prevents protection, may occlude this regular linear conformation. We suggest that mucosal immunization with CWPS primes T(H)17 cells, which - upon contact with the phosphocholine of colonizing pneumococci - elaborate IL-17A, enhancing phagocytosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19577628      PMCID: PMC2737138          DOI: 10.1016/j.micpath.2009.06.008

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  36 in total

1.  CD4-T-lymphocyte interactions with pneumolysin and pneumococci suggest a crucial protective role in the host response to pneumococcal infection.

Authors:  Aras Kadioglu; William Coward; M Joseph Colston; Colin R A Hewitt; Peter W Andrew
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

2.  Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci.

Authors:  R Malley; M Lipsitch; A Stack; R Saladino; G Fleisher; S Pelton; C Thompson; D Briles; P Anderson
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

3.  Intranasal immunization with protein-linked phosphorylcholine protects mice against a lethal intranasal challenge with streptococcus pneumoniae.

Authors:  S Trolle; E Chachaty; N Kassis-Chikhani; C Wang; E Fattal; P Couvreur; B Diamond; J Alonso; A Andremont
Journal:  Vaccine       Date:  2000-07-01       Impact factor: 3.641

4.  Effect of molecular size on the ability of zwitterionic polysaccharides to stimulate cellular immunity.

Authors:  W M Kalka-Moll; A O Tzianabos; Y Wang; V J Carey; R W Finberg; A B Onderdonk; D L Kasper
Journal:  J Immunol       Date:  2000-01-15       Impact factor: 5.422

5.  Limited role of antibody in clearance of Streptococcus pneumoniae in a murine model of colonization.

Authors:  Tera L McCool; Jeffrey N Weiser
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

6.  CD4+ T cells mediate abscess formation in intra-abdominal sepsis by an IL-17-dependent mechanism.

Authors:  Doo Ryeon Chung; Dennis L Kasper; Ronald J Panzo; Tanuja Chitnis; Michael J Grusby; Mohamed H Sayegh; Arthur O Tzianabos; Tanuja Chtinis
Journal:  J Immunol       Date:  2003-02-15       Impact factor: 5.422

7.  Cross-reactivity of human immunoglobulin G2 recognizing phosphorylcholine and evidence for protection against major bacterial pathogens of the human respiratory tract.

Authors:  Hannah B Goldenberg; Tera L McCool; Jeffrey N Weiser
Journal:  J Infect Dis       Date:  2004-08-31       Impact factor: 5.226

8.  A unique variant of streptococcal group O-antigen (C-polysaccharide) that lacks phosphocholine.

Authors:  Niklas Bergström; Per-Erik Jansson; Mogens Kilian; Uffe B Skov Sørensen
Journal:  Eur J Biochem       Date:  2003-05

9.  Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice.

Authors:  Zhe Zhang; Thomas B Clarke; Jeffrey N Weiser
Journal:  J Clin Invest       Date:  2009-06-08       Impact factor: 14.808

10.  Polysaccharide processing and presentation by the MHCII pathway.

Authors:  Brian A Cobb; Qun Wang; Arthur O Tzianabos; Dennis L Kasper
Journal:  Cell       Date:  2004-05-28       Impact factor: 41.582

View more
  7 in total

Review 1.  The yin yang of bacterial polysaccharides: lessons learned from B. fragilis PSA.

Authors:  Neeraj K Surana; Dennis L Kasper
Journal:  Immunol Rev       Date:  2012-01       Impact factor: 12.988

Review 2.  Serotype-independent pneumococcal experimental vaccines that induce cellular as well as humoral immunity.

Authors:  Richard Malley; Porter W Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-02       Impact factor: 11.205

3.  Controlled inflammatory responses in the lungs are associated with protection elicited by a pneumococcal surface protein A-based vaccine against a lethal respiratory challenge with Streptococcus pneumoniae in mice.

Authors:  Fernanda A Lima; Daniela M Ferreira; Adriana T Moreno; Patrícia C D Ferreira; Giovana M P Palma; Jorge M C Ferreira; Isaias Raw; Eliane N Miyaji; Paulo L Ho; Maria Leonor S Oliveira
Journal:  Clin Vaccine Immunol       Date:  2012-07-03

4.  Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice.

Authors:  Maria Leonor S Oliveira; Eliane N Miyaji; Daniela M Ferreira; Adriana T Moreno; Patricia C D Ferreira; Fernanda A Lima; Fernanda L Santos; Maria Aparecida Sakauchi; Célia S Takata; Hisako G Higashi; Isaías Raw; Flavia S Kubrusly; Paulo L Ho
Journal:  PLoS One       Date:  2010-05-27       Impact factor: 3.240

Review 5.  Rationale and prospects for novel pneumococcal vaccines.

Authors:  Kristin Moffitt; Richard Malley
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

6.  A Combination of Recombinant Mycobacterium bovis BCG Strains Expressing Pneumococcal Proteins Induces Cellular and Humoral Immune Responses and Protects against Pneumococcal Colonization and Sepsis.

Authors:  Cibelly Goulart; Dunia Rodriguez; Alex I Kanno; Thiago Rojas Converso; Ying-Jie Lu; Richard Malley; Luciana C C Leite
Journal:  Clin Vaccine Immunol       Date:  2017-10-05

7.  Distinct effects on diversifying selection by two mechanisms of immunity against Streptococcus pneumoniae.

Authors:  Yuan Li; Todd Gierahn; Claudette M Thompson; Krzysztof Trzciński; Christopher B Ford; Nicholas Croucher; Paulo Gouveia; Jessica B Flechtner; Richard Malley; Marc Lipsitch
Journal:  PLoS Pathog       Date:  2012-11-08       Impact factor: 6.823

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.